



28th March, 2017

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza", C-1, Block G,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref. : (i) Symbol – DISHMAN
(ii) Series – EQ

Sub. : Clarification pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
Ref.: You're Letter No. NSE/CM/Surveillance/6710 dated 28th March, 2017 regarding
Confirmation/Information on published news

Dear Sir/Madam,

With reference to your letter no. NSE/CM/Surveillance/6710 dated 28th March, 2017 regarding Confirmation/Information on published news, we would like to clarify on the same as under:

"We are a Global Contract Research and Manufacturing Services ("CRAMS") company specializing in developing and manufacturing Active Pharmaceutical Ingredients ("APIs") for our customers. Currently, we have about thirteen molecules in late phase III development across various customers. We, as an API supplier, are bound by strict confidentiality agreements with our customers and will not have any prior knowledge of the stage of development of the customer's end product. We believe that the increase in the stock price is based upon market estimation that we are one of the suppliers of the API for "Zejula" capsules, which got approved by the US FDA as per the press release given by Tesaro Inc.


Since the company does not manufacture the innovator's end product in CRAMS segment, it is Tesaro Inc., which has received the US FDA approval for cancer drug Zejula Capsules and not Dishman Pharmaceuticals and Chemicals Limited, as mentioned in the news item, which appeared on CNBC TV18 dated March 28, 2017."

The Company has always been fully compliant and inform to Stock Exchanges of such information which is required under regulation 30 of SEBI (LODR) Regulation, 2015.

Hope the above clarifications will satisfy your requirements. If you need any further clarification kindly inform to us.

Thanking you.
Yours faithfully,

For, Dishman Pharmaceuticals and Chemicals Limited


Shrima Dave
Company Secretary



Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329